The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown. In this pilot study we determined the effects of empagliflozin 10 mg/d for 4 weeks on peak oxygen consumption (VO 2 ) in 15 patients with T2DM and HFrEF. As an exploratory analysis, we assessed whether there was an interaction of the effects of empagliflozin on peak VO 2 of loop diuretics. Empagliflozin reduced body weight (−1.7 kg; P = .031), but did not change peak VO 2 (from 14.5 mL kg HFrEF. However, as a result of exploratory analysis, patients concomitantly treated with loop diuretics experienced a significant improvement in peak VO 2 .
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The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown. In this pilot study we determined the effects of empagliflozin 10 mg/d for 4 weeks on peak oxygen consumption (VO 2 ) in 15 patients with T2DM and HFrEF. As an exploratory analysis, we assessed whether there was an interaction of the effects of empagliflozin on peak VO 2 of loop diuretics. Empagliflozin reduced body weight (−1.7 kg; P = .031), but did not change peak VO 2 ; P = .95). However, patients using loop diuretics (N = 9) demonstrated an improvement, whereas those without loop diuretics (N = 6) experienced a decrease in peak VO 2 (+0.9 [0.1-1.4] vs −0.9 [−2.1 to −0.3] mL kg −1 min −1 ; P = .001), and peak VO 2 changes correlated with the baseline daily dose of diuretics (R = +0.83; P < .001). Empagliflozin did not improve peak VO 2 in patients with T2DM and HFrEF. However, as a result of exploratory analysis, patients concomitantly treated with loop diuretics experienced a significant improvement in peak VO 2 .
cardiorespiratory fitness, diuretics, empagliflozin, heart failure, SGLT2 inhibitors Peak VO 2 is a strong independent predictor of events and is sensitive for detecting the efficacy of therapeutic interventions in HF patients. 5 Importantly, peak VO 2 , measured by ventilatory expired gas analysis, is not biased by overexertion, and is insensitive to the placebo effect. 5, 7 Physical activity was assessed using the International Physical Activity Questionnaire-short version (IPAQ). The IPAQ-short is a 7-question questionnaire that estimates physical activity by assessing responses to questions concerning duration and intensity of daily physical activity.
| Cardiac function assessment
We assessed cardiac function using transthoracic Doppler echocardiography to measure LV end-diastolic and end-systolic volume, LVEF, early transmitral velocities (E) at pulsed wave Doppler spectra, early mitral annulus velocities by tissue Doppler averaged between lateral and septal (e 0 ), and we calculated the E/e 0 ratio. 
| Diuresis, natriuresis and RAAS activation assessments
We assessed the effects of empagliflozin on 24-hour diuresis, urinary sodium concentration (Na + UR) and RAAS activation, measured as plasma renin activity (PRA), aldosterone plasma levels (ALD) and ALD/PRA ratio, following overnight fasting and after suspension of angiotensin II antagonists (ATII-A) and mineralocorticoid-receptor antagonists (MRA) for 24 hours. Chemical laboratory analyses were performed using clinical standard assays (LabCorp, Burlington, North Carolina).
| Dietary sodium, body weight and waist circumference assessments
Dietary sodium intake can affect fluid status and RAAS activation; therefore, we estimated sodium intake using a standardized 5-pass interview 24-hour dietary recall, as previously described. 10 Body weight and waist circumference were measured on the day of RAAS activation assessment. Waist circumference was measured according to the World Health Organization recommendations. 3 | RESULTS
| Baseline characteristics
Among the patients, 8 (53%) were women, 9 (60%) were White and 6 (40%) were Black Americans, median age was 60 (56-62) years, and body mass index (BMI) was 34 (31-37) kg/m 2 . All patients were using ATII-A; 7 patients (47%) were using MRA and 9 (60%) patients were using loop diuretics. Median HbA1c was 7.8% (7.2-8.6), NTproBNP was 229 pg/mL (47-657), creatinine was 1.1 mg/dL (0. ; P = .95) in the overall cohort, nor did it change IPAQ-estimated physical activity (P = .59).
We found a large variability in changes in peak VO 2 , ranging from −2.9 to +2.5 mL kg −1 min 
| Loop diuretic use and effects on peak VO 2
A statistically significant interaction between loop diuretic use (9 [60%]) and effects on peak VO 2 was found, for both peak VO 2 relative to body weight ( Figure 1A ) (P = .001) and absolute peak VO 2 (P = .001), showing a dose-dependent relationship between diuretic dose and peak VO 2 changes (R = +0.83; P < .001) ( Figure 1B ), without differences in physical activity and blood pressure changes between the 2 groups (P = .28 and P = .77, respectively). The change in Na + UR ( Figure 1C ) and in the ALD/PRA ratio also correlated positively with changes in peak VO 2 (R = +0.622; P = .023 and R = +0.52; P = 0.057, respectively). Neither ATII-A nor MRA doses correlated with changes in Na + UR, PRA or ALD/PRA (all P > .05).
When investigating potential contributors to peak VO 2 changes in the overall cohort, the statistically significant predictors at univariate analysis were BMI, waist circumference, HbA1c and loop diuretic dose, but diuretic dose remained the only significant predictor for peak VO 2 changes at multivariate analysis (β coefficient = .623; P = .013).
A significant interaction between diuretic use and the effects of empagliflozin on Na + UR was also found, showing a reduction in Na + UR, a surrogate for renin activation 12 in patients treated with empagliflozin without loop diuretics, but not in those treated with loop diuretics (−32% vs 0%, respectively; P = .031). We found a non- significant trend for PRA changes without and with diuretics (+50% vs −22%, respectively; P = .21) and a significant interaction between use of diuretics and the ALD/PRA ratio, a more accurate marker for renin activation (decrease in ratio) vs aldosterone hypersecretion (increase) (−66% vs +26%, respectively; P = .028) ( Figure 1D ). Finally, we found a significant association between changes in resting diastolic BP and aldosterone plasma level changes (R = −0.55; P = .03). However, neither systolic nor diastolic resting BP were associated with changes in CRF (both P > .30).
| DISCUSSION
The data presented herein show, for the first time, that SGLT-2 inhibition with empagliflozin was associated with a highly heterogeneous response in terms of peak VO 2 , Na Our study is however, limited by the small sample size and by the absence of assessment of O 2 delivery and/or utilization, which could have also affected the overall results, including the absence of significant improvements in fasting glycaemia. Specifically, that may be the result of our study being underpowered to detect changes in fasting glycaemia. However, we cannot exclude the possibility that the effects of empagliflozin in patients with established HFrEF are less pronounced than in non-HFrEF patients, or that it requires more time to achieve a similar effect, clearly requiring further and larger studies, specifically in the HFrEF population. 14 Moreover, changes in CRF did not simply reflect interval changes in physical activity which, however, was estimated using a subjective questionnaire that may not be as sensitive as other means such as accelerometers.
SGLT-2 inhibitors reduced HF-related events in randomized clinical trials 1,2 and in real-world data 15 ; however, the effects of this class in well-characterized patients with established HFrEF, and more specifically, the effects on peak VO 2 , remain unknown.
Here we report an interaction between empagliflozin and use of loop diuretics in patients with HFrEF, an interaction that was interestingly posited in a recent clinical trial. 2, 16 The implications would be that the use of empagliflozin in HFrEF patients not treated with loop diuretics may be less beneficial. If confirmed in larger studies evaluating the role of SGLT-2 inhibitors, specifically in patients with HFrEF, this could greatly influence the clinical applications of these agents.
